Status:
ACTIVE_NOT_RECRUITING
Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)
Lead Sponsor:
Weill Cornell Medical College in Qatar
Collaborating Sponsors:
Procter and Gamble
Hamad Medical Corporation
Conditions:
Peripheral Neuropathy
Painful Neuropathy
Eligibility:
All Genders
18+ years
Brief Summary
This study is looking at people with diabetes (type 1 and type 2 diabetes) to see how well a short questionnaire, called the ACT, can identify nerve damage in the feet and legs (also known as peripher...
Detailed Description
This a cross-sectional cohort study in patients with diabetes with the aim of assessing the validity and diagnostic accuracy of the ACT questionnaire in identifying peripheral neuropathy (PN) in patie...
Eligibility Criteria
Inclusion
- Patients with diabetes (T1DM and T2DM)
- Age ≥18
- Able to provide consent.
- Able to sit still for corneal confocal microscopy
Exclusion
- Failure to provide informed consent
- Participants with a history of ocular trauma or previous ocular surgery in the preceding 6 months, are allergic to oxybuprocaine or local anesthetics or unable to cooperate by holding still or placing their chin on an optical device
- Other causes of peripheral neuropathy: vitamin B12 deficiency; hypothyroidism; myeloma.
- Cognitively impaired participants
- Pregnant women
- Nursing women
Key Trial Info
Start Date :
May 11 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07163000
Start Date
May 11 2025
End Date
December 30 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medicine-Qatar
Doha, Qatar, 24144